ADXN Addex Therapeutics
- 9.1000
- +0.0999+1.11%
Addex Therapeutics News
Addex Therapeutics | 6-K: Report of foreign private issuer (related to financial reporting)
Addex Therapeutics | 6-K: Report of foreign private issuer (related to financial reporting)
Addex Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Addex Therapeutics | 424B3: Prospectus
Addex Therapeutics | EFFECT: Others
Addex Therapeutics | POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing
Addex Therapeutics | 20-F: Registration statement / Annual report / Transition report
Addex Therapeutics | 6-K: Report of foreign private issuer (related to financial reporting)
Addex Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Addex Therapeutics | 424B5: Prospectus
Addex Therapeutics | 6-K: Report of foreign private issuer (related to financial reporting)
Addex Therapeutics | 6-K/A: Report of foreign private issuer (related to financial reporting)
Addex Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Addex Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Addex Therapeutics | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Growth Equity Opportunities Fund IV, LLC(6.4%),New Enterprise Associates 15, L.P.(6.4%), etc.
Addex Therapeutics | 424B3: Prospectus
Addex Therapeutics | EFFECT: Others
Addex Therapeutics | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Timothy Mark Dyer(14.16%)
Addex Therapeutics | POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing
Addex Therapeutics | 6-K: Report of foreign private issuer (related to financial reporting)
Analysis
Price Target
No Data
